Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Embol-X Inc.

Division of Edwards Lifesciences Corp.

Latest From Embol-X Inc.

Embolic Protection: Working the Guidewire With a Net

At this year's Paris Course on Revascularization (PCR), the leading European interventional meeting, embolic protection devices (EPDs) were among the prime subjects, in terms of clinical presentations and company exhibits. Some industry executives had predicted that Medtronic's acquisition last fall of PercuSurge would end the competitive race in this market before it really began. But judging by both the newer companies at the PCR and other recent entrants into this space, it appears that the battle has just begun. There are around 14 companies now competing in this space, six of which have received CE mark. Since none of these companies is on the US market, the initial competitive battle will be fought in Europe. Each of the major cardiology companies has already gotten into this area, generally through acquisitions. But there are also several start-ups that have come up with new technological approaches that are receiving favorable initial clinical reviews, so the debate remains open as to which of three approaches--occlusion balloons, filters, or proximal occlusion/reverse flow systems will ultimately prevail.

Medical Device Innovation

Boston Scientific: An Acquiror Once More

Once an aggressive buyer of promising device technology, Boston Scientific's recent difficulties relegated it to the M&A sidelines; the company is back with a new string of acquisitions but a different gameplan.

Medical Device Innovation

Clogged Plumbing

Two years ago, OmniSonics, a small medical device firm with a promising application in BPH, ran into a brick wall in discussions with investors; some of that was due to dot-com mania, but investors also evinced distaste for the urology and gynecology markets. A poor industry track record, compounded by reimbursement troubles, cautious physician adopters, and patients sometimes reluctant to seek treatment, had left earlier investors in the space feeling burned. But there's reason to hope that investor skittishness will begin to fade. Not only is the market driven by strong demographics, but also social and cultural taboos are coming down. For all its problems, for many device companies, particularly for large ones, the opportunity in urology and gynecology may soon become too attractive to turn down.

Medical Device Leadership

Cool is Hot: The Promise of Hypothermia

Medical researchers have known for more than 50 years that cold can be an important cardio- and neuroprotectant, but concerns about the side effects of deep hypothermia and sloppy, time-consuming procedures turned physicians away. Advances in device design as well as new research on the value of mild hypothermia have unlocked the potential of the therapy to function as a temperature management tool in surgery and critical care, to protect against injury from emboli in cardiac surgery, in resuscitation and trauma, and perhaps the biggest opportunities, in stroke and heart attacks.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Edwards Lifesciences Corp.
  • Senior Management
  • Yue-Teh Jang, PhD, Pres. & CEO
  • Contact Info
  • Embol-X Inc.
    Phone: (650) 390-0280
    645 Clyde Ave.
    Mountain View, CA 94043